Published in J Clin Endocrinol Metab on March 01, 1993
Effects of Glucagon Administration on Energy Expenditure (GLEE) | NCT02237053
Disorders of glucose metabolism-post mortem analyses in forensic cases: part I. Int J Legal Med (2010) 0.84
Octreotide's role in the management of sulfonylurea-induced hypoglycemia. J Med Toxicol (2010) 0.83
Treatment of sulfonylurea and insulin overdose. Br J Clin Pharmacol (2016) 0.80
Toxicology case of the month: oral hypoglycaemic overdose. Emerg Med J (2006) 0.79
Hypoglycemia revisited in the acute care setting. Yonsei Med J (2011) 0.79
Case files of the Medical Toxicology Fellowship Training Program at the Children's Hospital of Philadelphia: a pediatric exploratory sulfonylurea ingestion. J Med Toxicol (2006) 0.76
Bench-to-bedside review: Antidotal treatment of sulfonylurea-induced hypoglycaemia with octreotide. Crit Care (2005) 0.76
Use of octreotide acetate to prevent rebound hypoglycaemia in sulfonylurea overdose. Emerg Med J (2007) 0.75
Unwitnessed sulphonylurea poisoning in a healthy toddler. Eur J Pediatr (2010) 0.75
Subclinical hypothyroidism in a biethnic, urban community. J Am Geriatr Soc (1999) 3.05
A prospective trial of risk factors for sulfonylurea-induced hypoglycemia in type 2 diabetes mellitus. JAMA (1998) 2.29
Persisting mortality in diabetic ketoacidosis. Diabet Med (1993) 2.28
Thiazolidinediones for type 2 diabetes. New agents reduce insulin resistance but need long term clinical trials. BMJ (2000) 2.08
Prehepatic insulin production in man: kinetic analysis using peripheral connecting peptide behavior. J Clin Endocrinol Metab (1980) 1.99
Brain glucose uptake and unawareness of hypoglycemia in patients with insulin-dependent diabetes mellitus. N Engl J Med (1995) 1.87
The efficacy of self-monitoring of blood glucose in the management of patients with type 2 diabetes treated with a gliclazide modified release-based regimen. A multicentre, randomized, parallel-group, 6-month evaluation (DINAMIC 1 study). Diabetes Obes Metab (2008) 1.59
Contraindications to metformin therapy in patients with NIDDM. Diabetes Care (1997) 1.49
Meal composition is a determinant of lispro-induced hypoglycemia in IDDM. Diabetes Care (1997) 1.48
Diminished brain glucose metabolism is a significant determinant for falling rates of systemic glucose utilization during sleep in normal humans. J Clin Invest (1994) 1.47
A 'fail-safe' screening programme for diabetic retinopathy. J R Coll Physicians Lond (1998) 1.40
Adaptation in brain glucose uptake following recurrent hypoglycemia. Proc Natl Acad Sci U S A (1994) 1.40
Insulin suppresses its own secretion in vivo. Diabetes (1987) 1.31
Detection of antibody to hepatitis-associated antigen in hemophilia patients and in voluntary blood donors. Vox Sang (1973) 1.29
Hepatic removal of insulin in normal man: dose response to endogenous insulin secretion. J Clin Endocrinol Metab (1983) 1.21
The regulation of plasma ketone body concentration by counter-regulatory hormones in man. III. Effects of norepinephrine in normal man. Diabetes (1979) 1.16
In search of the subcutaneous-insulin-resistance syndrome. N Engl J Med (1986) 1.16
Practical guidance on intensification of insulin therapy with BIAsp 30: a consensus statement. Int J Clin Pract (2009) 1.13
Sulphonylurea-induced hypoglycaemia in type 2 diabetes mellitus: a review. Diabetes Obes Metab (1999) 1.09
Short-term fasting is a mechanism for the development of euglycemic ketoacidosis during periods of insulin deficiency. J Clin Endocrinol Metab (1993) 1.08
Predicting the occurrence of diabetes mellitus in recipients of heart transplants. Diabet Med (2000) 1.07
The etiology of incapacitating, brittle diabetes. Diabetes Care (1985) 1.04
Successful treatment of severe refractory sulfonylurea-induced hypoglycemia with octreotide. Diabetes Care (1993) 0.98
Effects of insulin infusion on plasma phosphate in diabetic patients. Metabolism (1979) 0.97
The kinetics of peritoneal insulin absorption. Metabolism (1981) 0.96
Dynamics of insulin and glucagon secretions in severely burned patients. J Trauma (1977) 0.95
A biethnic community survey of cognition in participants with type 2 diabetes, impaired glucose tolerance, and normal glucose tolerance: the New Mexico Elder Health Survey. Diabetes Care (2001) 0.95
Differential effects of fasting and dehydration in the pathogenesis of diabetic ketoacidosis. Metabolism (2001) 0.95
Prevalences of type 2 diabetes, the insulin resistance syndrome, and coronary heart disease in an elderly, biethnic population. Diabetes Care (1998) 0.94
Euglycaemic diabetic ketoacidosis: does it exist? Acta Diabetol (1993) 0.93
Dose response to insulin in man: differential effects on glucose and ketone body regulation. J Clin Endocrinol Metab (1977) 0.91
Modulation of fatty acid metabolism by glucagon in man. I. Effects in normal subjects. Diabetes (1975) 0.90
Pathogenesis of diabetic ketoacidosis: a reappraisal. Diabetes Care (1980) 0.90
Octreotide: a long-acting inhibitor of endogenous hormone secretion for human metabolic investigations. Metabolism (1994) 0.90
"Normal" insulin secretion: the goal of artificial insulin delivery systems? Diabetes Care (1980) 0.89
Metabolic effects of clofibrate in insulin-dependent ketosis-prone diabetic man. Metabolism (1978) 0.89
Underestimation of hepatic glucose production by radioactive and stable tracers. Am J Physiol (1987) 0.86
The role of glucagon in the regulation of plasma lipids. Metabolism (1979) 0.85
Optimal administration of lispro insulin in hyperglycemic type 1 diabetes. Diabetes Care (1999) 0.85
Five-day programmed intraperitoneal insulin delivery in insulin-dependent diabetic man. J Clin Endocrinol Metab (1981) 0.85
Chlorpropamide-induced hypoglycemia: successful treatment with diazoxide. Am J Med (1977) 0.85
Normalization of plasma insulin profiles with intraperitoneal insulin infusion in diabetic man. Diabetologia (1980) 0.85
The peritoneum--a potential insulin delivery route for a mechanical pancreas. Diabetes Care (1980) 0.85
A remotely programmable insulin delivery system. Successful short-term implantation in man. JAMA (1982) 0.85
Diabetes medication patient safety incident reports to the National Reporting and Learning Service: the care home setting. Diabet Med (2011) 0.84
Anthropometric, metabolic, and immunological effects of recombinant human growth hormone in AIDS and AIDS-related complex. J Acquir Immune Defic Syndr (1993) 0.84
The peritoneal absorption of insulin in diabetic man: a potential site for a mechanical insulin delivery system. Metabolism (1979) 0.84
Overproduction of a kinetic subclass of VLDL-apoB, and direct catabolism of VLDL-apoB in human endogenous hypertriglyceridemia: an analytical model solution of tracer data. J Lipid Res (1983) 0.84
The regulation of plasma ketone body concentration by counterregulatory hormones in man. Diabetes (1977) 0.84
The effect of short term physiological elevations of plasma glucagon concentration on plasma triglyceride concentration in normal and diabetic man. Horm Metab Res (1977) 0.84
The temporal relationship between endogenously secreted stress hormones and metabolic decompensation in diabetic man. J Clin Endocrinol Metab (1980) 0.84
Modified hospital pumps for pulsed insulin delivery. Med Prog Technol (1980) 0.83
Metabolic and clinical significance of ketosis. Spec Top Endocrinol Metab (1982) 0.83
Benefits and risks of transfer from oral agents to insulin in type 2 diabetes mellitus. Drug Saf (1999) 0.82
Differential effects of physiological versus pathophysiological plasma concentrations of epinephrine and norepinephrine on ketone body metabolism and hepatic portal blood flow in man. Metabolism (1996) 0.82
Myocardial atrophy in acquired immunodeficiency syndrome--associated wasting. Am Heart J (1995) 0.82
The intravenous, intraperitoneal, and subcutaneous routes of insulin delivery in diabetic man. Diabetes (1979) 0.82
The role of catecholamines in metabolic acidosis. Ciba Found Symp (1982) 0.81
Modulation of fatty acid metabolism by glucagon in man. II. Effects in insulin-deficient diabetics. Diabetes (1975) 0.81
Comparative efficacy of a once-daily controlled-release formulation of glipizide and immediate-release glipizide in patients with NIDDM. Diabetes Care (1994) 0.81
Effect of short-term glucose control on glycemic thresholds for epinephrine and hypoglycemic symptoms. J Clin Endocrinol Metab (2001) 0.81
A clinical algorithm to determine the etiology of brittle diabetes. Diabetes Care (1985) 0.81
Metabolic and hormonal effects of tacrolimus (FK506) or cyclosporin immunosuppression following renal transplantation. Diabetes Obes Metab (2001) 0.80
Future therapy of the insulin-dependent diabetic patient--the implantable insulin delivery system. Diabetes Care (1981) 0.80
Recent developments and emerging therapies for type 2 diabetes mellitus. Drugs R D (1999) 0.80
The controversy concerning counterregulatory hormone secretion. A hypothesis for the prevention of diabetic ketoacidosis? Diabetes (1977) 0.80
Diastolic function is strongly and independently associated with cardiorespiratory fitness in central obesity. J Appl Physiol (1985) (2010) 0.80
The regulation of plasma ketone body concentration by counter-regulatory hormones in man. II. Effects of growth hormone in diabetic man. Diabetes (1978) 0.80
Diabetic ketoacidosis--pathogenesis, prevention and therapy. Clin Endocrinol Metab (1983) 0.80
Diabetic glucose control: matching plasma insulin concentration to dietary and stress hyperglycemia. Diabetes Care (1981) 0.79
The pathogenesis of peritoneal adhesions: an ultrastructural study. Ann Surg (1968) 0.79
Implantation of an artificial pancreas. Current perspectives. JAMA (1981) 0.79
Should cisapride be avoided in patients with diabetic gastroparesis? J Diabetes Complications (2000) 0.79
The metabolic response to norepinephrine in normal versus diabetic man. Diabetologia (1978) 0.79
Subcutaneous peritoneal access device for type I diabetic patients nonresponsive to subcutaneous insulin. Diabetes (1982) 0.78
Insulins. Endocrinol Metab Clin North Am (1997) 0.78
Electron microscopy of insulin precipitates. Diabetes Care (1983) 0.78
Insulin removal in man: in vivo evidence for a receptor-mediated process. J Clin Endocrinol Metab (1984) 0.78
Normalization of plasma insulin profiles in diabetic subjects with programmed insulin delivery. Diabetes Care (1980) 0.78
Modulation of fatty acid metabolism by glucagon in man. IV. Effects of a physiologic hormone infusion in normal man. Diabetes (1976) 0.78
Effect of clofibrate on arginine-stimulated glucagon and insulin secretion in man. Metabolism (1974) 0.78
Differential diagnosis and therapy of hyperketonemic state. JAMA (1979) 0.78
Endogenous glucagon regulation in genetically hyperlipemic obese rats. Am J Physiol (1976) 0.77
Insulin resistance in the regulation of lipolysis and ketone body metabolism in non-insulin dependent diabetes is apparent at very low insulin concentrations. Diabetes Res Clin Pract (1993) 0.77
Low-dose ethanol predisposes elderly fasted patients with type 2 diabetes to sulfonylurea-induced low blood glucose. Diabetes Care (1999) 0.77
The contribution of endogenous insulin secretion to the ketogenic response to glucagon in man. Diabetologia (1975) 0.77
Glucagon regulation of plasma ketone body concentration in human diabetes. J Clin Invest (1975) 0.77
Outcome of recruitment and report on participation rate in the New Mexico Elder Health Survey. Ethn Dis (1998) 0.77
Use of the HemoCue blood glucose analyzer in research studies. Diabetes Care (1998) 0.77
Metabolic heterogeneity of low density lipoprotein-apoB production in familial hypercholesterolemia: an analytical model solution of tracer data. J Lipid Res (1982) 0.77
Prolonged efficacy of short acting insulin Lispro in combination with human ultralente in insulin-dependent diabetes mellitus. J Clin Endocrinol Metab (1997) 0.77
Severe relapsing sulphonylurea-induced hypoglycaemia: a diagnostic and therapeutic challenge. Postgrad Med J (2003) 0.76
Role of insulin and glucagon in obesity. Diabetes (1974) 0.76
Addition of sulfonylurea to insulin treatment in poorly controlled type II diabetes. A double-blind, randomized clinical trial. JAMA (1987) 0.76
The ketotic ratio (KB/NEFA) in man. Clin Exp Pharmacol Physiol (1981) 0.76
Letter: Hypomagnessemia as a cause of persistent hypokalemia. JAMA (1975) 0.76
Factitious brittle diabetes mellitus. Am J Med (1985) 0.76
Glucagon resistance as a hormonal basis for endogenous hyperlipaemia. Lancet (1973) 0.76